3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
2
Melanoma
2
Uveal Melanoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
47
Cyclophosphamide
45
fludarabine
22
Filgrastim
21
Lenalidomide
18
fludarabine phosphate
17
Prednisone
16
Radiotherapy
15
Peripheral Blood Stem Cell Transplantation
15
Etoposide
15
Vincristine
14
Doxorubicin
14
Melphalan
13
Busulfan
13
pembrolizumab
11
Tacrolimus
11
Methotrexate
10
Gemcitabine
10
ibrutinib
9
Bendamustine Hydrochloride
9
Alemtuzumab
9
obinutuzumab
8
Bortezomib
8
Vorinostat
7
Mycophenolic Acid
7
Granulocyte Colony-Stimulating Factor
7
Carboplatin
7
Azacitidine
7
venetoclax
6
Whole-Body Irradiation
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma
×
Valproic Acid
×
Clear all
NCT01622439
2018-03-12
VALFRID
Lund University Hospital
Phase 1/2
Completed
50 enrolled